Last updated: December 8, 2023
Sponsor: BioXcel Therapeutics Inc
Overall Status: Terminated
Phase
3
Condition
Dementia
Manic Disorders
Williams Syndrome
Treatment
BXCL501
Matching Placebo
Clinical Study ID
NCT05665088
BXCL501-304
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AAcriteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AAdiagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011NIA-AA criteria
- Episodes of psychomotor agitation (e.g., kick, bite, flailing)
- Subjects exhibit behaviors that are congruent with the International PsychogeriatricAssociation criterion for agitation representing a change from the subject's usualbehavior
- A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to fullassistance with activities of daily living
- Subjects who read, understand, and provide written informed consent, or who have a LARto provide consent on their behalf
- Subjects who are deemed to be medically appropriate for study participation by theprincipal investigator
- Participants who agree to use a medically acceptable and effective birth controlmethod
Exclusion
Exclusion Criteria:
- Subjects with dementia or other memory impairment not due to probable AD.
- Clinical diagnosis of probable AD should not be applied when there is evidence of acerebrovascular incident temporally related to the worsening of cognitive function.
- Subjects with agitation caused by acute intoxication.
- Subjects with significant risk of suicide or homicide per the investigator'sassessment.
- Subjects who are medically unstable or in recovery. Note: Subjects with a remote (>5years) history of stroke may be included, regardless of size/location.
- History of clinically significant syncope or syncopal attacks, orthostatic hypotensionwithin the past 2 years, current evidence of hypovolemia, orthostatic hypotension,bradycardia.
- Subjects with laboratory or ECG abnormalities.
- Subjects who have received an investigational drug within 30 days prior to Screening.
- Subjects who are currently suffering from substance abuse.
- Subjects with a potential cause for delirium (relatively recent onset agitation anddementia)
Study Design
Total Participants: 13
Treatment Group(s): 2
Primary Treatment: BXCL501
Phase: 3
Study Start date:
December 14, 2022
Estimated Completion Date:
September 11, 2023
Study Description
Connect with a study center
BioXcel Clinical Research Site
Los Alamitos, California 90720
United StatesSite Not Available
BioXcel Clinical Research Site
Daytona Beach, Florida 32117
United StatesSite Not Available
BioXcel Clinical Research Site
Maitland, Florida 32751
United StatesSite Not Available
BioXcel Clinical Research Site
The Villages, Florida 32162
United StatesSite Not Available
BioXcel Clinical Research Site
Marrero, Louisiana 70072
United StatesSite Not Available
BioXcel Clinical Research Site
Springfield, Massachusetts 01103
United StatesSite Not Available
BioXcel Clinical Research Site
Toms River, New Jersey 08755
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.